For breast cancer treatments that do not express PRKD1, pan- inhibitors of PRKD could be even more effective if used in combination with PRKD2 or PRKD3's current chemotherapeutic agents have been associated to mediate multi-drug resistance 43, 57. Here, PRKD3 is linked to breast carcinoma.